Clinical-stage biotechnology company developing programmable cell and gene therapies using a proprietary synthetic biology Gene Circuit platform
Clinical-stage biotechnology company developing programmable cell and gene therapies using a proprietary synthetic biology Gene Circuit platform. Its pipeline includes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapies designed to improve cancer-cell targeting, spare healthy cells, and control therapeutic gene expression.